42 reports

  • Global Tuberculosis (TB) Drugs Market is Expected to Grow to $1,035.67 mn by 2021
  • 2.1 Preface
  • Pathology
  • Tuberculosis
  • World
  • Forecast
  • Sandoz Inc.

Individual majorly suffer from two predominant forms of TB: Active tuberculosis and Latent tuberculosis.

  • Tuberculosis
  • Asia
  • North America
  • World
  • Forecast
  • Tuberculosis Treatment Drugs Market Overview
  • Top 10 Tuberculosis Drugs Sales Volume and Their
  • Tuberculosis
  • China
  • Demand
  • Trade
  • Chongqing Huapont Pharmaceutical Co., Ltd
  • Profiles of Tuberculosis Drugs Producers
  • Top 10 Tuberculosis Drugs Sales Volume and Their
  • Tuberculosis
  • China
  • Demand
  • Market Size
  • Shandong Lukang Pharmaceutical Co., Ltd

Based on Therapeutics the market is categorized into Tuberculosis Drugs (First Line) and Tuberculosis Drugs (Second Line).

  • Therapy
  • Tuberculosis
  • United States
  • World
  • Forecast
  • Epistem Holdings Plc Pipeline Products by Indication
  • Oct 28, 2014: Successful completion of Genedrive Indian clinical trials and regulatory submission
  • Tuberculosis
  • India
  • World
  • Epistem Holdings Plc
  • GlobalData's company
  • Profiles of Tuberculosis Drugs Producers
  • CHAPTER VII TUBERCULOSIS DRUGS PRODUCER DIRECTORY
  • Tuberculosis
  • China
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Shenyang Shuangding Pharmaceutical Co., Ltd.
  • Brazil: Segmentation of TB Diagnostic Tests by Revenue 2012-2013
  • 05. Introduction

Introduction TB is an infectious disease caused by the bacterium, Mycobacterium tuberculosis.

  • Tuberculosis
  • World
  • Market Size
  • Alere Inc.
  • Roche Group

Tuberculosis Diagnostics Market Size And Forecast By Test Types And Trend Analysis From 2013 to 2024 Table of Content Chapter ## Research Methodology ##. ## Research Methodology ##. ## Research Scope & Assumptions ##. ## List of Data Sources Chapter ## Executive Summary Chapter ## Market Summary Ch

  • Diagnostics
  • Laboratory
  • Pathology
  • Tuberculosis
  • Market Size

People majorly suffer from two forms of TB: active tuberculosis and latent tuberculosis.

  • Pathology
  • Tuberculosis
  • World
  • Market Size
  • Tuberculosis Location
  • Miliary Tuberculosis in Tuberculosis patients with HIV, total (000s)
  • Healthcare
  • Pathology
  • Tuberculosis
  • Europe
  • Peptides for Tuberculosis
  • TUBERCULOSIS - PIPELINE BY GLAXOSMITHKLINE PLC, H1 2017
  • DNA
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile
  • Jun 06, 2016: Speeding up drug discovery to fight tuberculosis
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.
  • SMALL MOLECULES TO INHIBIT DNA GYRB FOR TUBERCULOSIS
  • PIPELINE BY ASTRAZENECA PLC, H2 2017
  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC
  • TUBERCULOSIS VACCINE - DRUG PROFILE
  • TUBERCULOSIS VACCINE - DRUG PROFILE
  • Tuberculosis
  • Vaccine
  • South Africa
  • World
  • Product Initiative
  • Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis
  • Pipeline by Johnson & Johnson, H2 2016
  • Antibiotic Resistance
  • Tuberculosis
  • World
  • Product Initiative
  • Lycera Corp.
  • tuberculosis vaccine - Drug Profile
  • Mycobacterium tuberculosis Protein Ag85A Overview
  • Tuberculosis
  • Vaccine
  • South Africa
  • World
  • Product Initiative
  • 8.2 TUBERCULOSIS
  • THE TUBERCULOSIS DISEASE SEGMENT TO DOMINATE THE RESPIRATORY
  • Diagnostics
  • Hospital
  • Tuberculosis
  • Market Size
  • Alere Inc.
  • Pulmonary Tuberculosis Therapeutics, E7 Countries, Clinical Trials by Trial Status,...
  • Pulmonary Tuberculosis Therapeutics Market, Global, Clinical Trials by Sponsor Type...
  • Anti-Infective
  • Therapy
  • Tuberculosis
  • World
  • Product Initiative
  • Official Title
  • Tuberculosis Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Clinical Trial
  • Infectious Disease
  • Tuberculosis
  • World
  • TB Drug Development, Inc.
  • MBIO DIAGNOSTIC ASSAY - TUBERCULOSIS - PRODUCT DESCRIPTION
  • MBIO DIAGNOSTIC ASSAY - TUBERCULOSIS - PRODUCT STATUS
  • Diagnostics
  • Tuberculosis
  • United States
  • Company
  • MBio Diagnostics, Inc.
  • SANOFI ENTERS INTO RESEARCH AGREEMENT WITH TB ALLIANCE TO ADVANCE TREATMENTS FOR TUBERCULOSIS
  • NOVARTIS ENTERS INTO LICENSING AGREEMENT WITH GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT FOR TUBERCULOSIS...
  • Pathology
  • Pharmaceutical
  • Tuberculosis
  • World
  • TB Drug Development, Inc.
  • TUBERCULOSIS VACCINE
  • TUBERCULOSIS - PIPELINE BY ELI LILLY AND COMPANY, H2 2016
  • Tuberculosis
  • World
  • Company
  • Product Initiative
  • TB Drug Development, Inc.

Tuberculosis Vaccine ## Aeras Enters Into Co-Development Agreement With Infectious Disease Research Institute For ID##/ GLA-SE ## Aeras Enters Into Co-Development Agreement With Tianjin CanSino For Tuberculosis Vaccine ## Aeras Enters Into Co-Development Agreement With China

  • Pathology
  • Tuberculosis
  • Vaccine
  • World
  • M&A
  • PARTNERSHIPS

We look forward to working with our counterparts at Aeras to develop new TB vaccines that will help stop tuberculosis in all corners of the world. "

  • Pathology
  • Tuberculosis
  • China
  • Corporate Finance
  • GlobalData's company
  • Parasitic Diseases, Pulmonary Tuberculosis
  • Official Title
  • Drug Discovery And Development
  • Tuberculosis
  • World
  • Product Initiative
  • TB Drug Development, Inc.
  • Application
  • Application
  • Genomics
  • Tuberculosis
  • United States
  • Product Initiative
  • GlobalData's company
  • Application
  • Application
  • Genomics
  • Tuberculosis
  • United States
  • Product Initiative
  • GlobalData's company
  • Transgene SA - Pipeline by Indication, 2015
  • Product Description

It offers TG## and various candidates for chronic hepatitus B and tuberculosis.

  • Genetically Modified Organism
  • Therapy
  • Transgene
  • Tuberculosis
  • Transgene SA
  • Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203
  • Qurient Raises USD25.7 Million in IPO
  • Healthcare
  • Tuberculosis
  • South Korea
  • Company
  • Qurient Co., Ltd.